425: PrimeGen US to Go Public via DT Cloud Star SPAC Merger

PrimeGen US, a biotech company focused on stem cell and exosome therapies, announced a definitive business combination agreement with DT Cloud Star Acquisition Corporation, implying an equity value of approximately $1.5 billion.

Summary

• DT Cloud Star Acquisition Corporation (DTCS) and PrimeGen US, Inc. (PrimeGen) announced a definitive business combination agreement dated February 2, 2026.
• The transaction implies an equity value for PrimeGen US of approximately $1.5 billion.
• The combined company is expected to operate as PrimeGen US and is anticipated to list on Nasdaq under a new ticker symbol, subject to Nasdaq approval.
• The transaction is expected to close in the second half of 2026, subject to stockholder approvals, regulatory approvals (including Hart-Scott-Rodino), minimum cash conditions, and other customary closing conditions.
• PrimeGen US is a regenerative medicine company leveraging nearly two decades of proprietary stem cell research to develop Triple Activated Mesenchymal Stem Cells (MSCs) as a novel, cell-based treatment for acute liver injury and related critical conditions.
• PrimeGen US completed a Pre-Investigational New Drug (Pre-IND) meeting for Acute Alcoholic Hepatitis (Acute Liver Failure) with the U.S. Food & Drug Administration (FDA) on December 17, 2025.
• The company is working towards initiating a clinical trial for Triple Activated MSCs for Acute Alcoholic Hepatitis, subject to regulatory approval.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it provides PrimeGen US with a clear path to public capital and validation of its technology, but significant execution risks remain in clinical development and regulatory approval.

Positives

• The transaction implies an equity value for PrimeGen US of approximately $1.5 billion.
• The business combination is expected to provide access to public markets capital to advance clinical development, regulatory activities, and potential commercialization of lead programs.
• PrimeGen US leverages nearly two decades of proprietary stem cell research, positioning it in the regenerative medicine field.
• Completion of a Pre-Investigational New Drug (Pre-IND) meeting with the FDA for Acute Alcoholic Hepatitis on December 17, 2025, marks a step forward in regulatory engagement.
• The combined entity is believed to be uniquely positioned to deliver much-needed regenerative medicine and capture large unmet market opportunities.

Negatives

• There is no assurance regarding the timing or completion of the transaction.
• Preclinical results may not be indicative of clinical outcomes in humans.
• There is no assurance that the FDA will allow an IND to proceed or that any clinical trials will be successful.

Risks

• The Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of DTCS's securities.
• The Business Combination may not be completed by DTCS's business combination deadline, and there is a potential failure to obtain an extension if sought.
• Failure to satisfy the conditions to the consummation of the Business Combination, including shareholder approvals, closing requirements, and governmental/regulatory/third-party approvals.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Business Combination Agreement.
• Redemptions by DTCS shareholders exceeding anticipated levels.
• Failure to meet Nasdaq initial listing standards in connection with the consummation of the Business Combination.
• The effect of the announcement or pendency of the Business Combination on PrimeGen's business relationships, operating results, and business generally.
• Risks that the Business Combination disrupts current plans and operations of PrimeGen.
• The outcome of any legal proceedings that may be instituted against Parent Parties and PrimeGen related to the Business Combination Agreement or the Business Combination.
• The inherent uncertainty of clinical success and the risk that trials may be delayed or fail to meet primary endpoints.
• Changes in domestic and global general economic conditions.
• The possibility that FDA or other regulatory authorities may not approve candidates or may require additional data.
• Compliance with emerging regulations, including the BIOSECURE Act, and other applicable regulations and their impact on manufacturing and supply chain partnerships.
• The risk that DTCS may not be able to develop and maintain effective internal controls.
• Costs related to the Business Combination and the failure to realize anticipated benefits or estimated pro forma results and underlying assumptions, including with respect to estimated shareholder redemptions.
• Inability to recognize the anticipated benefits of the Business Combination and to achieve commercialization and development plans, and identify and realize additional opportunities, which may be affected by competition, the ability of PrimeGen to grow and manage growth economically, and the ability to hire and retain key employees.
• Inability to achieve successful results or to obtain licensing of third-party intellectual property rights for future discovery and development of PrimeGen's projects.
• Failure to commercialize products and achieve market acceptance of such products.
• The risk that PrimeGen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.
• The risk of product liability or regulatory lawsuits or proceedings relating to PrimeGen's business.
• Risks associated with intellectual property protection and the risk that PrimeGen is unable to secure or protect its intellectual property.

Future Outlook

The combined company expects to use public markets capital to advance clinical development, regulatory activities, and potential commercialization of its lead programs. PrimeGen US is working towards initiating a clinical trial for Triple Activated MSCs for Acute Alcoholic Hepatitis, subject to regulatory approval. The transaction is expected to close in the second half of 2026.

Management Comments

• "We are thrilled to partner with DT Cloud Star to bring PrimeGen US into the public markets at this pivotal moment. This transaction is expected to enhance our access to capital and resources, supporting the continued development of our stem cell and exosome programs. Our teams scientific focus and innovation position us to further build our presence in the regenerative medicine field." Daniel Chiu, Co-CEO and Chairman of PrimeGen US.
• "With nearly two decades of foundational stem cell technology as our launchpad, we have developed our Triple Activated MSC platform into a differentiated platform under development that we believe is well positioned to advance through its next stages of development, subject to regulatory review." Wai Szeto, Co-CEO of PrimeGen US.
• "We are pleased to partner with PrimeGen US in this business combination. We have great confidence that under the leadership of Co-CEOs Daniel Chiu and Wai Szeto, the company is uniquely positioned to deliver much-needed regenerative medicine to treat challenging diseases, such as acute liver failure. By leveraging PrimeGens nearly two decades of research and their Triple Activated MSC platform, we believe the combined entity will successfully capture large unmet market opportunities and provide significant value to patients and shareholders alike." Sam Zheng Sun, Chairman and CEO of DT Cloud Star Acquisition Corporation.

Industry Context

StockSavvy.ai notes that this SPAC merger highlights the continued trend of biotech companies, particularly those in the regenerative medicine and cell therapy space, seeking public market access to fund capital-intensive clinical development. The focus on stem cell and exosome therapies for conditions like acute liver injury positions PrimeGen US in a high-growth, high-risk segment of the biotech industry, where successful clinical trials and regulatory approvals are critical for market validation and commercialization.

Legal Proceedings

• Risk of legal proceedings that may be instituted against Parent Parties and PrimeGen related to the Business Combination Agreement or the Business Combination.
• Risk of product liability or regulatory lawsuits or proceedings relating to PrimeGen's business.

Stakeholder Impact

• Shareholders of DTCS will vote on the business combination and face risks related to redemptions and meeting listing standards.
• Shareholders of PrimeGen US gain access to public markets capital and liquidity, with an implied equity value of $1.5 billion.
• Employees of PrimeGen US may see growth and expanded opportunities as the company advances its development programs.
• Patients could potentially benefit from new regenerative medicine treatments for acute liver failure, contingent on successful clinical trials and regulatory approvals.
• Regulatory authorities, particularly the FDA, will be involved in reviewing IND applications, clinical trial data, and ultimately approving product candidates.

Next Steps

• Purchaser intends to file a registration statement on Form S-4 (including a proxy statement/prospectus) with the SEC.
• The SEC must declare the Registration Statement effective.
• The definitive proxy statement/prospectus will be mailed to DTCS shareholders.
• A meeting of DTCS shareholders will be held to vote on the Business Combination and related matters.
• PrimeGen US is working towards the initiation of a clinical trial for Triple Activated MSCs for Acute Alcoholic Hepatitis, subject to regulatory approval.
• The closing of the transaction is expected in the second half of 2026.

Key Dates

Recommendation

The announcement of a definitive business combination with an implied equity value of $1.5 billion for PrimeGen US is a significant event for DT Cloud Star Acquisition Corporation. While the transaction offers PrimeGen US access to public capital for advancing its stem cell and exosome therapies, the biotech company is still in preclinical stages for its lead program, with clinical trials subject to regulatory approval. The numerous risks associated with SPAC mergers, clinical development, regulatory hurdles, and market acceptance warrant a cautious approach. Investors should hold their positions in DTCS, awaiting further clarity on the merger's completion, PrimeGen's clinical progress, and the combined entity's financial outlook.

Keywords

SPAC, Business Combination, Biotech, Stem Cell Therapy, Exosome Therapy, Regenerative Medicine, Acute Liver Injury, Acute Alcoholic Hepatitis, FDA, Clinical Trials, Nasdaq Listing, DT Cloud Star Acquisition Corporation, PrimeGen US